Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.93

-0.6%

Dec 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (14184)	11/17/2004 4:43:53 PM
From: Arthur Radley	Read Replies (1) of 52153

Peter, I don't think it is a case of them having a problem getting it approved by the FDA. I think it is an issue dealing with the fact that Thalomid no longer has patent protection and Celgene is selling it for leprosy and wasting disease and apparently they have a delivery system that protects women of childbearing age from using the drug. I think the low cost(profit margin) and not having an proprietary protection has kept other companies from taking the drug through phase testing...leaving Celgene in the "cat-bird" seat! I could be wrong on this issue!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next